A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Metastatic Breast Cancer

In brief

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer

Key facts

Study ID

NCT04538742

Run by

AstraZeneca

People needed

245

Starts

2020-12-28

Expected to finish

2030-01-31

Last updated by the study team

2025-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — St. Petersburg, Florida, United States
• Research Site — Commack, New York, United States
• Research Site — Harrison, New York, United States
• Research Site — New York, New York, United States
• Research Site — New York, New York, United States
• Research Site — Columbus, Ohio, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — Fort Worth, Texas, United States
• Research Site — Fairfax, Virginia, United States
• Research Site — Melbourne, Australia
• Research Site — Barretos, Brazil
• Research Site — Belo Horizonte, Brazil
• Research Site — Natal, Brazil
• Research Site — Porto Alegre, Brazil
• Research Site — Porto Alegre, Brazil
• Research Site — Rio de Janeiro, Brazil
• Research Site — São Paulo, Brazil
• Research Site — São Paulo, Brazil
• Research Site — Sorocaba, Brazil
• Research Site — Montreal, Quebec, Canada
• Research Site — Québec, Quebec, Canada
• Research Site — Toronto, Canada
• Research Site — Villejuif, France
• Research Site — München, Germany
• Research Site — Fort Myers, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.